Evidence Pricing and Access Congress features advice from Stratence Partners
The World Evidence, Pricing and Access Congress has taken place in Amsterdam, working to help healthcare experts get the most from their resources in 2025. Leading two sessions at the event was Fernando Ventureira, CEO of Stratence Partners.
World Evidence, Pricing and Access (EPA) Congress is Europe’s largest annual gathering of market access, pricing, and evidence professionals. Taking place in March 2025, this year’s event was staged at the RAI Congress Centre in Amsterdam, hosting over 250 speakers and attracting more than 1,500 attendees from the pharmaceutical, biotech, and payer sectors.
With healthcare professionals facing shortfalls in funding, and pharmaceutical and research players under pressure to help address a number of global health concerns, the 2025 edition of the World EPA Congress offered a two-day programme. New to this year was the introduction of the Health Economics & Outcomes Research (HEOR) track and a dedicated poster area, designed to enhance the academic presence and deepen the discussions within the community.
As well as continuing to emphasise core areas such as market access and pricing, rare diseases, and HTA/Payer dynamics, the event additionally covered the latest trends in reimbursement, payment models, affordability, and HEOR, among other pivotal developments in the industry – providing a platform for showcasing solutions and thought leadership to key stakeholders across the pharmaceutical and biotech sectors.
The 2025 event delivered this programme by collaborating with a range of global advisory and solution providers, including Valid Insight, RXData, Lifescience Dynamics, and Parexel. Also at the event to present expertise was Stratence Partners – an international strategy consultancy. The firm’s CEO Fernando Ventureira was a featured speaker, delivering two critical sessions on healthcare digital transformation and pricing excellence.
“With rising costs and evolving regulations, pricing strategy is a competitive advantage,” Ventureira said via the firm’s website, after his sessions offered “a practical roadmap to maximise financial sustainability”. His talks also explained how organisations can build and scale digital transformation projects for long-term success, leverage AI and automation for efficiency and patient care, and turn digital investment into measurable profitability.
A statement from the firm following the event added that "as usual, the EPA Conference has been a fantastic opportunity to meet with pharma professionals and share insights on the industry". In particular, Ventureira's session on the topic of “Strategic Gross-To-Net Best Practices in Healthcare” had a significant impact, "with a full-packed room and more than 10 organisations waiting a the end of the event for having more detailed discussions with Fernando."
The firm concluded, "It is clear than more and more, pharma companies are investing in strengthening their capabilities on gross-to-net (people, data, analytics, processes, governance, organisation) as a way to improve the access to treatments in the benefits of patients, building new ways of relationships, and benefitting the business performance of their organisations by optimising their strategy, enhancing their pricing excellence and making more efficient their commercial functions."
